Equity Of Cancer Screening And Follow-up For Lung Cancer

Overview

About this study

The purpose of this study is to elucidate factors that contribute to lung cancer disparities between rural and urban areas and provide contextual information for future interventions and policies. Our specific aims are to: (1) Characterize the delivery of evidence-based interventions (EBIs) for lung cancer prevention and early detection, comparing rural to urban areas, by assessing differences in use of smoking cessation interventions and lung cancer screening (LCS) at multiple levels of influences; (2) Identify potentially modifiable care gaps across the LCS continuum, including risk assessment and timely treatment, by examining patients who died of lung cancer relative to patients who are alive by rural-urban status; and (3) Evaluate similarities and differences in the barriers and promoters to delivery of EBIs across the LCS continuum (smoking cessation, shared decision-making, screening, and treatment) in the rural and urban contexts. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Our study population will be men and women aged 50-80 years old during 2014-2023 who reside in communities across the rural-urban continuum. We will use both REP (n=326,088) and SCCS (n=71,099) data in parallel to characterize racially and socioeconomically diverse cohorts in the SCCS and among people who receive primary care in the MCHS and at FQHCs. The proposed studies include the involvement of human subjects in 90 semistructured interviews with patients (n=60) and healthcare professionals (n=30). Eligible patients include community-dwelling men and women who are 50-80 years old, eligible for lung cancer screening per the USPSTF guideline (20-pack-year of smoking), and are part of the cohort in the REP or the SCCS. We will identify eligible persons using the sampling frame of people 50-80 years old during 2014-2023 from the REP or the SCCS cohort. The REP is linked with the EHR. We will also interview health care professionals who are directly involved in the delivery of lung cancer screening within the MCHS and FQHCs participating in the SCCS. For Aims 1 and 2, which do not involve direct contact with the people studied, we will assemble an estimated dynamic retrospective cohort of 326,088 eligible people between 2014 and 2023 in the REP and an estimated 71,099 from the SCCS. SCCS had 65,868 people 50-80 years old and 5,231 people <50 years old as of January 1, 2014. The 71,099 is based on younger people aging into the cohort during follow-up period.

Exclusion Criteria:

  • Aim 1/Aim 2 excludes individuals under the age of 50 or over the age of 80. Rationale: Lung cancer is most common in individuals between the ages of 50 and 80 years. This age group is the focus of current national guidelines on lung cancer screening. This study will therefore exclude individuals under 50 or over 80.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/29/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Christi Patten, Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available